Associations between lifetime agoraphobia status at baseline and inflammatory measures at follow-up, fully adjusted model.

Values for inflammatory measures are given as unadjusted log10-transformed means ± standard deviation, values for interleukin-1β are given as prevalence.
HDL, high-density lipoprotein; CRP, C-reactive protein; TNF, tumor necrosis factor; OR, odds ratio; 95CI, 95% confidence interval.
a Duration between somatic evaluation at baseline and somatic evaluation at follow-up.
b Model adjusted for the inflammatory marker at baseline corresponding to the specific inflammatory marker at follow-up.
c A value of “3” represents an SES of III (middle class) on the Hollingshead Scale.
d Systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg.
e Physically active at least or more than 20 minutes twice a week.
f Generalized anxiety disorder, panic disorder, posttraumatic stress disorder, and/or social phobia.
g Marijuana, cocaine, solvent, hallucinogen, stimulant, sedative or/and narcotic dependence.
h Multiple regression with log10transformed cytokine or CRP or adiponectin.
i Logistic regression with interleukin-1β concentration dichotomized at the median.
j Composite score of inflammatory markers includes CRP, interleukin-6 and TNF-α. Only participants who had data available for all three of these markers were included in these analyses.
Associations between lifetime agoraphobia status at baseline and inflammatory measures at follow-up, fully adjusted model.